bioAffinity Technologies
Update in progressBIAF (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
bioAffinity Technologies, Inc. develops non-invasive diagnostic tests to detect early-stage lung cancer and other lung diseases using flow cytometry and automated analysis in the United States. It has two segments: Diagnostic Research and Development and Laboratory Services. Its CyPath Lung test analyzes sputum to identify cancer- and cancer-related cells shed from a tumor. The company collaborates with Brooke Army Medical Center on inflammatory biomarkers for asthma and COPD. Founded 2014, based in San Antonio, Texas.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMs. Maria Zannes J.D.
- Founded2014
- Employees57
- Websitebioaffinitytech.com
Identifiers
- ISINUS09076W1099
- FIGIBBG00H69JDX1
- CUSIP09076W307
- CIK0001712762